167 related articles for article (PubMed ID: 20399340)
1. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.
Kelly DL; Feldman S; Boggs DL; Gale E; Conley RR
Compr Psychiatry; 2010; 51(3):298-302. PubMed ID: 20399340
[TBL] [Abstract][Full Text] [Related]
2. [A new therapeutic approach tp drug-resistant schizophrenia: clozapine. Long-term prospective study in 16 patients].
Jalenques I; Coudert AJ
Acta Psychiatr Belg; 1992; 92(6):323-38. PubMed ID: 1364281
[TBL] [Abstract][Full Text] [Related]
3. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
4. [Clozapine and refractory schizophrenia. Long-term prospective study of 20 patients].
Jalenques I; Coudert AJ
Encephale; 1994; 20(6):767-75. PubMed ID: 7875111
[TBL] [Abstract][Full Text] [Related]
5. The brief psychiatric rating scale: effect of scaling system on clinical response assessment.
Thompson PA; Buckley PF; Meltzer HY
J Clin Psychopharmacol; 1994 Oct; 14(5):344-6. PubMed ID: 7806691
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.
Meltzer HY; Cola P; Way L; Thompson PA; Bastani B; Davies MA; Snitz B
Am J Psychiatry; 1993 Nov; 150(11):1630-8. PubMed ID: 8105705
[TBL] [Abstract][Full Text] [Related]
7. Deterioration in premorbid functioning in schizophrenia: a developmental model of negative symptoms in drug-free patients.
Kelley ME; Gilbertson M; Mouton A; van Kammen DP
Am J Psychiatry; 1992 Nov; 149(11):1543-8. PubMed ID: 1415823
[TBL] [Abstract][Full Text] [Related]
8. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.
Kronig MH; Munne RA; Szymanski S; Safferman AZ; Pollack S; Cooper T; Kane JM; Lieberman JA
Am J Psychiatry; 1995 Feb; 152(2):179-82. PubMed ID: 7840349
[TBL] [Abstract][Full Text] [Related]
9. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking.
Hasegawa M; Gutierrez-Esteinou R; Way L; Meltzer HY
J Clin Psychopharmacol; 1993 Dec; 13(6):383-90. PubMed ID: 8120151
[TBL] [Abstract][Full Text] [Related]
10. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome.
Lieberman JA; Safferman AZ; Pollack S; Szymanski S; Johns C; Howard A; Kronig M; Bookstein P; Kane JM
Am J Psychiatry; 1994 Dec; 151(12):1744-52. PubMed ID: 7977880
[TBL] [Abstract][Full Text] [Related]
11. Clozapine: efficacy and safety.
Buchanan RW
Schizophr Bull; 1995; 21(4):579-91. PubMed ID: 8749886
[TBL] [Abstract][Full Text] [Related]
12. Early response to clozapine in schizophrenia.
Stern RG; Kahn RS; Davidson M; Nora RM; Davis KL
Am J Psychiatry; 1994 Dec; 151(12):1817-8. PubMed ID: 7977893
[TBL] [Abstract][Full Text] [Related]
13. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment.
Meltzer HY; Thompson PA; Lee MA; Ranjan R
Neuropsychopharmacology; 1996 Mar; 14(3 Suppl):27S-33S. PubMed ID: 8866741
[TBL] [Abstract][Full Text] [Related]
14. Comparison of indices of premorbid function in schizophrenia.
DeQuardo JR; Goldman RS; Tandon R; McGrath-Giroux M; Kim L
Schizophr Res; 1995 May; 15(3):283-90. PubMed ID: 7632626
[TBL] [Abstract][Full Text] [Related]
15. Gender, premorbid characteristics and negative symptoms in schizophrenia.
Fennig S; Putnam K; Bromet EJ; Galambos N
Acta Psychiatr Scand; 1995 Sep; 92(3):173-7. PubMed ID: 7484193
[TBL] [Abstract][Full Text] [Related]
16. Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia.
Friedman L; Knutson L; Shurell M; Meltzer HY
Biol Psychiatry; 1991 May; 29(9):865-77. PubMed ID: 2049485
[TBL] [Abstract][Full Text] [Related]
17. A prospective 1-5 year outcome study in first-admitted and readmitted schizophrenic patients; relationship to heredity, premorbid adjustment, duration of disease and education level at index admission and neuroleptic treatment.
Wieselgren IM; Lindstrom LH
Acta Psychiatr Scand; 1996 Jan; 93(1):9-19. PubMed ID: 8919324
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoepidemiology of clozapine in 202 inpatients with schizophrenia.
Zito JM; Volavka J; Craig TJ; Czobor P; Banks S; Vitrai J
Ann Pharmacother; 1993 Oct; 27(10):1262-9. PubMed ID: 8251696
[TBL] [Abstract][Full Text] [Related]
19. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.
Hoff AL; Faustman WO; Wieneke M; Espinoza S; Costa M; Wolkowitz O; Csernansky JG
Neuropsychopharmacology; 1996 Oct; 15(4):361-9. PubMed ID: 8887990
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report.
Meltzer HY; Bastani B; Kwon KY; Ramirez LF; Burnett S; Sharpe J
Psychopharmacology (Berl); 1989; 99 Suppl():S68-72. PubMed ID: 2813667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
